Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progression phenotypes to anti-PD-(L)1 therapy and subsequent management of patients with metastatic NSCLC: A real-world cohort study.

Cancer treatment and research communications - 1 Jan 2026

Caballé-Pérez Enrique, Cabrera-Miranda Luis, Dávila-Dupont David, Hernández-Pedro Norma, Hernández-Martínez Juan-Manuel, Ramos-Ramírez Maritza, Lucio-Lozada José, Castillo-Ruiz Cesar, Cardona Andrés F, Cacho-Diaz Bernardo, Arrieta Oscar

Abstract excerpt

INTRODUCTION: Progression patterns to anti-PD-(L)1 therapies in metastatic NSCLC may have prognostic and therapeutic implications, but they remain incompletely characterized. MATERIALS AND METHODS: We retrospectively studied metastatic NSCLC who progressed to anti-PD-(L)1. First progression was classified as: oligoprogression (oligo-PD;≤3 lesions/organs) or systemic (systemic-PD); preexisting-lesion-only,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease Progression

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Neoplasm Metastasis

Share to Prognosis

Source

Identifiers

PMID: 41996947
DOI: 10.1016/j.ctarc.2026.101207

Genes

AR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progression phenotypes to anti-PD-(L)1 therapy and subsequent management of patients with metastatic NSCLC: A real-world cohort study.PMID 41996947Read ↗

Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers studySemantic proximity Read ↗

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.Semantic proximity Read ↗

Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer.Semantic proximity Read ↗

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.Semantic proximity Read ↗

PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.Semantic proximity Read ↗

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsSemantic proximity Read ↗

Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) BlockadeSemantic proximity Read ↗

Evaluation of the Updated 2022 Lung-GPA in NSCLC Adenocarcinoma Patients with Brain Metastases: Analysis of Prognostic Factors in a German Clinical CohortSemantic proximity Read ↗

Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs.Semantic proximity Read ↗

Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US.Semantic proximity Read ↗

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.Semantic proximity Read ↗

PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.